Combination of gonadotropin-releasing hormone (GnRH) agonists with GnRH antagonists before chemotherapy reduce but does not completely prevent a follicle-stimulating hormone flare-up.
Increasing evidence supports GnRH agonists to be an effective treatment to preserve ovarian function during chemotherapy, but the initial flare-up of FSH during the first week after GnRH agonist application still limits its use. The combination of GnRH agonists with GnRH antagonists might solve this problem to some extent as the addition of GnRH antagonists at least significantly reduces the FSH flare-up.
von Wolff
Michael
M
University Women's Hospital, Department of Gynaecological Endocrinology and Reproductive Medicine, Berne, Switzerland. Michael.vonWolff@insel.ch
Kämmerer
Ulrike
U
Kollmann
Zahraa
Z
Santi
Alessandro
A
Dietl
Johannes
J
Frambach
Torsten
T
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004958:Estradiol / Q000097:blood; D005260:Female; D005298:Fertility; D005640:Follicle Stimulating Hormone / Q000097:blood*; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists* / Q000037:antagonists & inhibitors*; D006801:Humans; D007247:Infertility, Female / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D007986:Luteinizing Hormone / Q000097:blood; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy; D016896:Treatment Outcome; D055815:Young Adult
D000970:Antineoplastic Agents; D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone